

THIS DOCUMENT AND THE ENCLOSED FORM OF PROXY ARE IMPORTANT AND REQUIRE YOUR IMMEDIATE ATTENTION. If you are in any doubt about the contents of this Document, or the action you should take, you are recommended to seek your own personal financial advice immediately from your stockbroker, bank manager, solicitor, accountant or other independent financial adviser authorised under the Financial Services and Markets Act 2000 (as amended) ("FSMA") if you are resident in the United Kingdom or, if not, from another appropriately authorised independent financial adviser.

If you have sold or transferred all of your Ordinary Shares, please send this Document and the accompanying Form of Proxy, as soon as possible to the purchaser or transferee or to the stockbroker, bank or other agent through whom the sale or transfer was effected for onward transmission to the purchaser or transferee. Such documents should, however, not be forwarded to or transmitted into any jurisdiction outside of the United Kingdom (including the United States) if to do so would constitute a violation of the relevant law and/or regulations of such jurisdiction. Any failure to comply with such restriction may constitute a violation of the securities laws of any such jurisdiction. If you have sold or transferred only part of your holding of Ordinary Shares, please contact your stockbroker, bank or other agent through whom the sale or transfer was effected immediately.

This Document does not constitute an offer to buy, acquire or subscribe for (or the solicitation of an offer to buy, acquire or subscribe for) Ordinary Shares or New Ordinary Shares. This Document does not contain an offer of relevant securities within the meaning of Regulation 12 of the Public Offers and Admissions to Trading Regulations 2024 and does not constitute a prospectus or MTF admission prospectus for the purposes of such regulations nor has it been prepared in accordance with the FCA's Prospectus Rules: Admission to Trading on a Regulated Market sourcebook. This Document has not been examined or approved by the Financial Conduct Authority or the London Stock Exchange or any other regulatory authority. In addition, this Document does not constitute an admission document drawn up in accordance with the AIM Rules for Companies. This Document has not been approved for issue by any person for the purposes of section 21 of FSMA.

MEDPAL AI PLC

(Registered and incorporated in England and Wales and governed by the law of England and Wales with Registered Number 13578804)

Notice of General Meeting

You should read the whole of this Document. Your attention is drawn to the letter from the Non-executive Director of the Company set out in this Document and which contains the Directors' unanimous recommendation that you vote in favour of the Resolutions to be proposed at the General Meeting.

A notice convening the General Meeting of the Company, to be held at the offices of Wedlake Bell LLP, 71 Queen Victoria Street, London, EC4V 4AY, at 10:00 a.m. on 29 October 2026 is set out at the end of this Document. A Form of Proxy for use at the General Meeting is enclosed and is also available on the Company's website at <https://medpalplc.com> and, to be valid, must be completed and returned to our registrar, Neville Registrars Limited, Neville House, Steelpark Road, Halesowen, West Midlands B62 8HD, as soon as possible but in any event to be received not later than 10:00 a.m. on 27 October 2026 or 48 hours (excluding any part of a day which is a non-working day) before any adjourned meeting. Proxy appointments should be submitted in accordance with the Notes to the General Meeting Notice at the end of this Document.

Cairn Financial Advisers LLP ("Cairn"), which is authorised and regulated in the United Kingdom by the Financial Conduct Authority (the "FCA"), is acting as nominated adviser to the Company. Persons receiving this Document should note that Cairn will not be responsible to anyone other than the Company for providing the protections afforded to customers of Cairn, or for advising any other person on the arrangements described in this Document. No representation or warranty, expressed or implied, is made by Cairn as to the

contents of this Document. Cairn has not authorised the contents of, or any part of, this Document and no liability whatsoever is accepted by Cairn for the accuracy of any information or opinions contained in this Document or for the omission of any information. Cairn, as nominated adviser to the Company, owes certain responsibilities to the London Stock Exchange which are not owed to the Company or the Directors.

A copy of this Document is available on the Company's website at <https://medpalplc.com>. Neither the content of the Company's website nor any website accessible by hyperlinks to the Company's website is incorporated in, or forms part of, this Document.

Cautionary note regarding forward-looking statements

Certain statements in this Document are forward-looking statements with respect to the Company's expectations, intentions and projections regarding its future performance, strategic initiatives, anticipated events or trends and other matters that are not historical facts and which are, by their nature, inherently predictive, speculative and involve risks and uncertainty because they relate to events and depend on circumstances that may or may not occur in the future. All statements that address expectations or projections about the future, including statements about operating performance, strategic initiatives, objectives, market position, industry trends, general economic conditions, expected expenditures, expected cost savings and financial results are forward-looking statements. Any statements contained in this Document that are not statements of historical fact are, or may be deemed to be, forward-looking statements. These forward-looking statements, which may use words such as "aim", "anticipate", "believe", "could", "intend", "estimate", "expect", "may", "plan", "project" or words or terms of similar meaning or the negative thereof, are not guarantees of future performance and are subject to known and unknown risks and uncertainties. There are a number of factors including, but not limited to, commercial, operational, economic and financial factors, that could cause actual results, financial condition, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. Many of these risks and uncertainties relate to factors that are beyond the Company's ability to control or estimate precisely, such as changes in taxation or fiscal policy, future market conditions, currency fluctuations, the behaviour of other market participants, the actions of governments or governmental regulators, or other risk factors, such as changes in the political, social and regulatory framework in which the Company operates or in economic or technological trends or conditions, including inflation, recession and consumer confidence, on a global, regional or national basis. Given those risks and uncertainties, readers are cautioned not to place undue reliance on forward-looking statements. Forward-looking statements speak only as of the date of this Document. Each of the Company, Cairn and Clear Capital and Merlin Partners and their respective affiliates and representatives expressly disclaims any obligation or undertaking to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise unless required to do so by applicable law or regulation.

By their nature, forward-looking statements involve risk and uncertainty because they relate to future events and circumstances. Actual results and developments could differ materially from those expressed or implied by the forward looking statements.

Forward-looking statements may and often do differ materially from actual results. Any forward-looking statements in this Document are based on certain factors and assumptions, including the Directors' current view with respect to future events and are subject to risks relating to future events and other risks, uncertainties and assumptions relating to the Group's operations, results of operations, growth strategy and liquidity. Whilst the Directors consider these assumptions to be reasonable based upon information currently available, they may prove to be incorrect. Save as required by law, the Company undertakes no obligation to publicly release the results of any revisions to any forward-looking statements in this Document that may occur due to any change in the Directors' expectations or to reflect events or circumstances after the date of this Document.

Notice to overseas persons

The distribution of this Document and/or the Form of Proxy in certain jurisdictions may be restricted by law and therefore persons into whose possession these documents come should inform themselves about and observe any such restrictions. Any failure to comply with these restrictions may constitute a violation of the securities laws of any such jurisdiction.

CONTENTS

Directors, Company Secretary and Advisers 4 Expected Timetable of Events 5 Definitions 6 Letter
from the Non-executive Director of the Company 8 Notice of General Meeting End of the Document

DIRECTORS, COMPANY SECRETARY AND ADVISERS

Directors Harvey Sinclair *Independent Non executive Director*

Jason Kingsley Drummond *Chief Executive Officer*

Justin Piers Drummond *Executive Director*

Adam Monaco *Finance Director*

Kevin Sean O'Neill *Non-executive Director*

Company Secretary Breams Secretaries Limited

Floor 8
71 Queen Victoria Street
London EC4V 4AY

Registered Office MedPal AI plc

Floor 8
71 Queen Victoria Street
London EC4V 4AY

Company Telephone +44 (0)7400 800 500

Nominated Adviser Cairn Financial Advisers LLP

Ninth Floor
107 Cheapside
London EC2V 6DN

Joint Broker Clear Capital Markets Limited

6th Floor, Wilson's Corner
23–25 Wilson Street
London EC2M 2DD

Joint Broker Merlin Partners LLP

90 Jermyn Street
London SW1Y 6JD
Wedlake Bell LLP 71

**Legal advisers to
the Company**

Queen Victoria Street
London EC4V 4AY

Registrar Neville Registrars Limited Neville House
Steelpark Road
Halesowen
West Midlands B62 8HD

EXPECTED TIMETABLE OF PRINCIPAL EVENTS

Time / Date

2026

Electronic publication of this Document by 10:00 a.m. on 9 October Posting of this Document to Shareholders 9 October

Latest time and date for receipt of individual 10:00 a.m. on 27 October
Forms of Proxy / electronic proxy appointments

Record date for attendance at the General Meeting 6.00 p.m. on 27 October General Meeting 10:00 a.m. on 29 October

Future times and dates are indicative only and are subject to change by the Company. If the expected timetable of events changes from the above, the Company will notify the Shareholders to this effect via Regulatory Information Service.

References to time in this Document are to London times.

DEALING CODES

LEI 984500EDP8B0A14CBA61 **ISIN** GB00BTRC7N37 **SEDOL** BTRC7N3

DEFINITIONS

The following definitions apply throughout this Document unless the context otherwise

requires: **Act** the Companies Act 2006, as amended from time to time;

AIM the market of that name operated by the London Stock Exchange; **AIM Rules** the AIM Rules for Companies published by the London Stock Exchange from time to time;

Articles the Articles of Association of the Company from time to time; **Board or Directors** the board of directors of the Company, as set out on page 4 of this Document; **Circular or Document** this Document;

Clear Capital Clear Capital Markets Limited, the Company's joint broker;

Company or MedPal MedPal AI plc;

CREST the paperless share settlement system and system for the holding and transfer of shares in uncertified form in respect of which Euroclear is the Operator (as defined in the CREST Regulations);

CREST Manual the manual, as amended from time to time, produced by Euroclear describing the CREST system and supplied by Euroclear to users and participants thereof;

CREST Regulations the Uncertificated Securities Regulations 2001 (SI 2001 No. 3755), as amended;

Euroclear Euroclear UK & International Limited, a company incorporated in England and Wales with registered number 02878738, whose registered office is at 33 Cannon Street, London EC4M 5SB, the operator of CREST; the UK Financial Conduct Authority;

FCA or Financial Conduct Authority

Form of Proxy the form of proxy for use in connection with the General Meeting which accompanies this Document;

General Meeting the general meeting of the Company, to be held on 29 October 2026 at 10:00 a.m. at the offices of Wedlake Bell LLP, 71 Queen Victoria Street, London, EC4V 4AY or any adjournment thereof;

Group the Company and its subsidiaries;

Last Practicable Date 8 October 2026, the latest practicable date prior to publication of this Circular;

London Stock Exchange London Stock Exchange Group plc;

Merlin Partners Merlin Partners LLP, the Company's joint broker;

Notice of General Meeting the notice convening the General Meeting which is set out at the end of this Document; **Ordinary Shares** ordinary shares of £0.0002 each in the capital of the Company;

Registrars the Company's registrars, being Neville Registrars Limited, of Neville House, Steelpark Road, Halesowen, West Midlands B62 8HD;

Regulatory Information Service the public of regulatory announcements and included within the list maintained on the FCA's website; a service approved by the FCA for the distribution to

Shareholders the holders of the Ordinary Shares;

UK or United Kingdom the United Kingdom of Great Britain and Northern Ireland; and

Warrants the Warrants to be issued to Clear Capital.

LETTER FROM THE NON-EXECUTIVE DIRECTOR OF THE COMPANY

MEDPAL AI PLC

(Registered and incorporated in England and Wales and governed by the law of England and Wales with Registered Number 13578804)

Directors
Harvey Sinclair

Jason Kingsley Drummond Justin Piers Drummond
Adam Monaco
Kevin Sean O'Neill

To the holders of Ordinary Shares Dear Shareholders,

9 October 2026

1. Introduction

Registered Office

MedPal AI plc

Floor 8, 71 Queen Victoria Street, London EC4V 4AY

Notice of General Meeting

I am pleased to send you details of the forthcoming General Meeting of MedPal AI plc (the “Company”). The General Meeting will be held on 29 October 2026 at 10:00 a.m. at the offices of Wedlake Bell LLP, 71 Queen Victoria Street, London, EC4V 4AY.

The purpose of this Document is to convene a General Meeting of Shareholders in order to put forward the resolutions set out in the enclosed Notice of General Meeting.

2. Background to the reasons for the Circular

At the time of its admission to trading on AIM (“Admission”), MedPal was a pre-revenue digital health business built around the MedPal app, an AI-powered consumer platform aggregating data from more than 100 wearables and health apps into a unified user profile. The Company’s admission document set out a strategy of growing the app through direct-to consumer, corporate wellness and B2B channels, and contemplated acquisitions of complementary businesses in the healthcare sphere, including online pharmacies and telehealth, that would operate alongside and interact with the MedPal app to provide users with extended functionality and a seamless service.

The MedPal app remains the core of the Company and provides access to the MedPal OS platform. Since Admission, however, MedPal has progressed from a pre-revenue digital health business to an operational healthcare group combining AI-powered wellness support, NHS pharmacy services, private weight management and care-home software. The Company has established automated dispensing operations in Swaffham and Runcorn through the acquisition of pharmacy assets, secured direct supply agreements with Eli Lilly and Novo Nordisk, launched its New Health weight-management clinic, developed MedPal Health OS and its AI health companion, Juno, and acquired eMARx, a provider of electronic medication administration record software. It has also established a Care UK pharmacy supply contract, expanded distribution of its wellness app through partnerships with Epassi and Independent Gyms, and obtained a secondary quotation in Frankfurt.

By 30 September 2026, the Group had generated more than £5 million in cumulative turnover, while its 6 October 2026 trading update reported more than 33,000 New Health customers and a Group annualised revenue run rate exceeding £38

million, based on trading between 1 and 30 September 2026. This annualised figure is an extrapolation of recent trading and does not represent revenue already earned or a forecast.

Some of the equity issued in the six months since 30 March, principally in the case of eMARx, has been used as consideration for acquisitions and where possible the Company has issued new ordinary shares in lieu of fees in order to preserve its cash resources. Alongside this, growth in sales has been even more rapid than the Directors had anticipated and meeting the high levels of customer demand and achieving the current rate of

trading would have been impossible without the equity funds that have been raised by the Company over the last six months. As a young company, the Group currently pays for its medication before it is delivered and subsequently receives payment from the NHS and receives rebates from GLP-1 suppliers and reimbursement of VAT from HMRC, creating a working capital gap that needed to be filled.

As a result of the issues of equity during the last six months, MedPal has exhausted the authorities granted by shareholders at its AGM on 30 March 2026. The Company has opened discussions with UK clearing banks regarding a working capital facility secured on its receivables and expects supplier credit terms to follow as its trading record lengthens. If a facility is secured, the Board would expect it to reduce the need to raise further equity to fund the Group's working capital cycle as growth continues, however the authority being sought by the Company will provide it with the ability, should it be necessary, to raise further funds, or issue Ordinary Shares as consideration should an acquisition opportunity arise, prior to the renewal of its authorities at its next AGM, expected to be in March 2027.

In addition, conditional on shareholder approval for the Resolutions being obtained, the Company intends to grant the remaining warrants to Clear Capital Markets Limited ("Warrants") as set out in its announcement of 6 October 2026.

We very much welcome shareholders wishing to attend in person and look forward to seeing you should you wish to do so. Shareholders should monitor the Investors section of the Company's website at www.medpalplc.com and the Company's Regulatory Information Service announcements for any updates in relation to the GM.

3. General Meeting and Resolutions

Set out at the end of this Document is a notice convening the General Meeting, to be held on 29 October 2026 at 10:00 a.m. at the offices of Wedlake Bell LLP, 71 Queen Victoria Street, London, EC4V 4AY.

A summary and explanation of the Resolutions which will be proposed at the General Meeting is

set out below. **Resolution 1: Authority to allot shares**

Resolution 1 will be proposed as an ordinary resolution. If passed, this resolution will provide authority up to an aggregate nominal amount of £2,810.05 for the Directors to grant the Warrants to Clear Capital Markets Limited and gives the Directors the general authority to allot ordinary shares in the Company and to grant rights to subscribe for, or convert securities into, ordinary shares up to an aggregate nominal amount of £160,000 (representing approximately 90 per cent. of the nominal value of the entire issued share capital of the Company at the Last Practicable Date).

Resolution 2: Disapplication of Pre-Emption Rights

Resolution 2 will be proposed as a special resolution. Subject to the passing of Resolution 1, it will empower the Directors pursuant to section 570 of the Act, to allot equity securities (as defined in section 560 of the Act) for cash as if the statutory pre-emption rights contained in section 561(1) of the Act did not apply. The Act requires that any equity securities issued wholly for cash must be offered to existing shareholders in proportion to their existing shareholdings unless otherwise approved by shareholders in a general meeting or accepted under the Articles. A special resolution will be proposed at the General Meeting to give the Directors authority to allot equity securities for cash other than on a pro rata basis in respect of the grant of the Warrants to Clear Capital Markets Limited and generally as noted above in relation to Resolution 1.

The authorities to be granted pursuant to Resolutions 1 and Resolution 2 will expire on whichever is the earlier of (a) the conclusion of the next Annual General Meeting of the Company; and (b) the date falling fifteen

months from the date of the passing of the Resolutions (unless renewed, varied or revoked by the Company prior to or on that date).

The authorities granted by Resolution 1 and Resolution 2 would revoke and replace all unexercised authorities previously granted to the Directors but without prejudice to any allotment or grant of equity securities already made or offered or agreed to be made pursuant to such authorities.

4. Action to be taken and proxy voting

Enclosed with this letter you will find the Notice of General Meeting and a Form of Proxy in respect of the General Meeting.

Whether or not you propose to attend the General Meeting in person, you are asked to complete the Form of Proxy and return it to our Registrar, Neville Registrars Limited, in accordance with the instructions included in the notes to this Document, so as to arrive as soon as possible, but in any event, so as not to be received any later than 10:00 a.m. on 27 October 2026.

Completion of a form of proxy or the appointment of a proxy electronically will not stop you from attending the meeting and voting in person should you so wish.

The proxy card enclosed with this Notice is also available on the Company's website at <https://medpalplc.com>. Please note the deadline for the receipt of proxies by our registrar, Neville Registrars Limited, Neville House, Steelpark Road, Halesowen, West Midlands B62 8HD, is 10:00 a.m. on 27 October 2026. Proxy appointments should be submitted in accordance with the Notes to the General Meeting Notice at the end of this Document.

Any corporation which is a shareholder can appoint one or more corporate representative(s) who may exercise on its behalf all of its powers as a shareholder.

Questions

Any member attending a general meeting has the right to ask questions in accordance with section 319A of the Companies Act 2006 and the Company must cause to be answered any such question relating to the business being dealt with at the meeting, unless to do so would interfere unduly with preparation for the meeting, involve the disclosure of confidential information, the answer has already been given on a website or it is undesirable in the interests of the Company or good order of the meeting that the question be answered.

5. Board Opinion and Recommendation

The Board of MedPal is committed to building long-term shareholder value through the development of the Company's digital health and AI business.

The Board considers that the resolutions to be proposed at the General Meeting to be in the best interests of the Company and its shareholders as a whole. The Directors unanimously recommend that you vote in favour of the resolutions as they intend to do in respect of their own beneficial holdings, which, in aggregate, amount to 212,698,648 Ordinary Shares in the Company, representing approximately 24 per cent. of the Company's issued ordinary share capital.

Yours sincerely,

Harvey Sinclair
Non-executive Director

MedPal AI plc

MEDPAL AI PLC

(Registered and incorporated in England and Wales and governed by the law of England and Wales with
Registered Number 13578804)

NOTICE OF GENERAL MEETING

NOTICE IS HEREBY GIVEN that the general meeting of the Company will be held at 10:00 a.m. on 29 October 2026 at the offices of Wedlake Bell LLP, 71 Queen Victoria Street, London, EC4V 4AY to consider and, if thought fit, to pass the following resolutions, of which Resolution 1 will be proposed as an ordinary resolution, and Resolution 2 will be proposed as a special resolution.

In each of the Resolutions below, terms defined in the circular to shareholders published by the Company dated 9 October 2026 ("**Circular**"), of which this notice forms a part, shall have the same meanings:

Ordinary Resolution

1. **THAT** the Directors be and are hereby generally and unconditionally authorised for the purpose of section 551 of the Companies Act 2006 (the "**Act**") to exercise all or any of the powers of the Company to allot equity securities (within the meaning of section 560 of the Act):

(a) up to an aggregate nominal amount of £2,810.05 in respect of the Warrants; and

(b) otherwise than pursuant to sub-paragraph (a) of this Resolution 1, up to an aggregate nominal amount of £160,000 in respect of equity securities, being approximately 90 per cent. of the aggregate nominal amount of the entire issued capital of the Company as at the Last Practicable Date,

provided that this authority shall, unless renewed, varied or revoked by the Company, expire on the earlier of (i) the conclusion of the next annual general meeting of the Company and (ii) the date which is 15 months from the date of the passing of the Resolution, save that the Company may, before such expiry, make an offer or agreement which would or might require equity securities to be allotted or granted after such expiry and the Directors may allot or grant equity securities in pursuance of such offer or agreement notwithstanding that the authority conferred by this Resolution has expired. This authority revokes and replaces all unexercised authorities previously granted to the Directors but without prejudice to any allotment or grant of equity securities already made or offered or agreed to be made pursuant to such authorities.

Special Resolution

2. **THAT**, subject to and conditional upon the passing of Resolution 1 above, the Directors be empowered under section 570 of the Act to allot equity securities (within the meaning of section 560 of the Act) pursuant to the authority conferred under section 551 of the Act by Resolution 1 above as if section 561 of the Act did not apply to any such allotments provided that this power shall be limited to:

(a) up to an aggregate nominal amount of £2,810.05 in respect of the Warrants; and

(b) otherwise than pursuant to sub-paragraph (a) of this Resolution 2, up to an aggregate nominal amount of £160,000 in respect of equity securities, being approximately 90 per cent. of the aggregate nominal amount of the entire issued capital of the Company as at the Last Practicable Date,

provided that the authority granted by this Resolution 2 shall expire on the earlier of 15 months from the

passing of this Resolution or the conclusion of the Company's next annual general meeting provided that the Company may before such expiry make offers or agreements which would or might require equity securities to be allotted after such expiry and the directors of the Company may allot equity securities under such offers or agreements as if the power conferred by this Resolution had not expired.

Dated: 9 October 2026

By Order of the Board

Registered Office:

MedPal AI plc
Floor 8, 71 Queen Victoria Street, London EC4V 4AY

Company Secretary Breams Secretaries Limited

Notes to the General Meeting

Appointment of proxies

1. As a member of the Company, you are entitled to appoint a proxy to exercise all or any of your rights to attend, speak and vote at the General Meeting and you should have received a Form of Proxy with this Notice of General Meeting. You can only appoint a proxy using the procedures set out in these notes and the notes to the Form of Proxy.
2. A proxy does not need to be a member of the Company but must attend the General Meeting to represent you. Details of how to appoint the Chair of the General Meeting or another person as your proxy using the Form of Proxy are set out in the notes to the Form of Proxy. If you wish your proxy to speak on your behalf at the General Meeting you must appoint your own choice of proxy (not the Chair) and give your instructions directly to the relevant person.
3. Any member entitled to attend and vote at the General Meeting is entitled to appoint one or more proxies (who need not be a member of the Company) to vote instead of the member. You may not appoint more than one proxy to exercise rights attached to any one share. To appoint more than one proxy, you must complete a separate Form of Proxy for each proxy and specify against the proxy's name the number of shares over which the proxy has rights. If you are in any doubt as to the procedure to be followed for the purpose of appointing more than one proxy you must contact the Neville Registrars Limited at Neville House, Steelpark Road, Halesowen, West Midlands B62 8HD. If you fail to specify the number of shares to which each proxy relates or specify a number of shares greater than that held by you on the record date, proxy appointments will be invalid.
4. If you do not indicate to your proxy how to vote on any resolution, your proxy will vote or abstain from voting at his discretion. Your proxy will vote (or abstain from voting) as he thinks fit in relation to any other matter which is put before the General Meeting. Appointment of proxy using the hard copy Form of Proxy.
5. The notes to the Form of Proxy explain how to direct your proxy how to vote on each resolution or withhold their vote.
6. To appoint a proxy using the Form of Proxy, it must be:
 - 6.1 completed and signed;
 - 6.2 sent by post to Neville Registrars Limited at Neville House, Steelpark Road, Halesowen, West Midlands B62 8HD or delivered by hand to Neville Registrars Limited at Neville House, Steelpark

Road, Halesowen, West Midlands B62 8HD; and

6.3 received by Neville Registrars Limited by 10:00 a.m. on 27 October 2026 and not later than 48 hours (excluding any part of a day which is a non-working day) before the time of the meeting or of any adjournment of the meeting.

7. In the case of a member which is a company, the Form of Proxy must be executed under its common seal or signed on its behalf by an officer of the company or an attorney for the company.
8. In order to be valid, any form of proxy and power of attorney or other authority under which it is signed, or a notarially certified or office copy of such power or authority, must reach the Company's registrars, Neville Registrars Limited, Neville House, Steelpark Road, Halesowen, West Midlands B62 8HD, not less than 48 hours (excluding any part of a day which is a non-working day) before the time of the meeting or of any adjournment of the meeting.
9. Pursuant to regulation 41 of the Uncertificated Securities Regulations 2001, the Company specifies that in order to have the right to attend and vote at the meeting (and also for the purpose of calculating how many votes a person entitled to attend and vote may cast), a person must be entered on the register of members of the Company by no later than the close of business two business days before the date of the meeting. Changes to entries on the register of members after this time shall be disregarded in determining the rights of any person to attend or vote at the meeting.
10. CREST members who wish to appoint a proxy or proxies through the CREST electronic proxy appointment service may do so by using the procedures described in the CREST Manual (available via www.euroclear.com). CREST Personal Members or other CREST sponsored members, and those CREST members who have appointed a service provider(s), should refer to their CREST sponsor or voting service provider(s), who will be able to take the appropriate action on their behalf.

In order for a proxy appointment or instruction made using the CREST service to be valid, the appropriate CREST message (a 'CREST Proxy Instruction') must be properly authenticated in accordance with Euroclear UK & International Limited's specifications, and must contain the information required for such instruction, as described in the CREST Manual (available via www.euroclear.com). The message, regardless of whether it constitutes the appointment of a proxy or is an amendment to the instruction given to a previously appointed proxy must, in order to be valid, be transmitted so as to be received by Neville Registrars Limited (CREST agent ID 7RA11) by 10:00 a.m. on 27 October 2026. For this purpose, the time of receipt will be taken to be the time (as determined by the time stamp applied to the message by the CREST Application Host) from which the issuer's agent is able to retrieve the message by enquiry to CREST in the manner prescribed by CREST. After this time any change of instructions to proxies appointed through CREST should be communicated to the appointee through other means.

CREST members and, where applicable, their CREST sponsors, or voting service providers should note that Euroclear UK & International Limited does not make available special procedures in CREST for any particular message. Normal system timings and limitations will, therefore, apply in relation to the input of CREST Proxy Instructions. It is the responsibility of the CREST member concerned to take (or, if the CREST member is a CREST personal member, or sponsored member, or has appointed a voting service provider, to procure that his CREST sponsor or voting service provider(s) take(s)) such action as shall be necessary to ensure that a message is transmitted by means of the CREST system by any particular time. In this connection, CREST members and, where applicable, their CREST sponsors or voting system providers are referred, in particular, to those sections of the CREST Manual concerning practical limitations of the CREST system and timings.

The Company may treat as invalid a CREST Proxy Instruction in the circumstances set out in Regulation 35(5)(a) of the Uncertificated Securities Regulations 2001.

Appointment of proxy by joint members

11. In the case of joint holders of shares, where more than one of the joint holders purports to appoint a proxy, only the appointment submitted by the most senior holder (being the first named holder in respect of the shares in the Company's register of members) will be accepted.

Changing proxy instructions

12. To change your proxy instructions simply submit a new proxy appointment using the method set out in paragraph 6 above. Note that the cut off time for receipt of proxy appointments specified in that paragraph also applies in relation to amended instructions. Any amended proxy appointment received after the specified cut off time will be disregarded.
13. Where you have appointed a proxy using the hard copy Form of Proxy and would like to change the instructions using another hard copy Form of Proxy, please contact Neville Registrars Limited as indicated in paragraph 3 above.
14. If you submit more than one valid proxy appointment, the appointment received last before the latest time for the receipt of proxies will take precedence.

Termination of proxy appointments

- 15 In order to revoke a proxy instruction you will need to inform Neville Registrars Limited by sending a signed hard copy notice clearly stating your intention to revoke your proxy appointment to Neville Registrars Limited as indicated in paragraph 3 above. In the case of a member which is a company, the revocation notice must be executed under its common seal or signed on its behalf by an officer of the company or an attorney for the company. Any power of attorney or any other authority under which the revocation notice is signed (or a duly certified copy of such power or authority) must be included with the revocation notice.
16. The revocation notice must be received by Neville Registrars Limited no later than 10:00 a.m. on 27 October 2026.
17. If you attempt to revoke your proxy appointment but the revocation is received after the time specified then, subject to paragraph 18 below, your proxy appointment will remain valid.
18. Completion of a form of proxy or the appointment of a proxy electronically (see below) will not stop you from attending the meeting and voting in person should you so wish. If you have appointed a proxy and attend the General Meeting in person, your proxy appointment will automatically be terminated.

Corporate shareholders

19. Any corporation which is a shareholder can appoint one or more corporate representative(s) who may exercise on its behalf all of its powers as a shareholder, provided that (A) a letter of representation will be required for each of the corporate representatives in relation to the shares that they have been appointed to exercise on behalf of the shareholder (in accordance with s.323 of the Companies Act 2006) and (B) if two or more representatives are appointed, they must each represent different shares whether or not they vote in the same way as each other.

Total voting rights

20. As at the Last Practicable Date, the Company's issued share capital comprised 886,249,135 ordinary

shares of £0.0002 each. Each ordinary share carries the right to one vote at a general meeting of the Company and therefore the total number of voting rights in the Company as at 8 October 2026 is 886,249,135.